Theregen, Inc. (Theregen) is a regenerative medicine company engaged in the development of cell-based therapies for patients with cardiac and peripheral vascular disease. The company designs and develops the product namely Anginera used for cardiovascular and vascular applications. It is similar to Dermagraft, an FDA-approved, cell-based wound management product. The product has the potential to treat diffuse small vessel disease associated with myocardial ischemia and can be used as an adjunct to revascularization procedures. Its research and development activity is principally into enabling the development of products for several large cardiovascular and vascular markets by technology asset acquisition. Theregen is headquartered in California, the US.